Research programme: asthma therapeutics - Chiesi USAAlternative Names: CRTX-809
Latest Information Update: 16 Jul 2016
At a glance
- Originator Cornerstone Therapeutics
- Developer Chiesi USA
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in USA
- 28 Apr 2014 Cornerstone Therapeutics is now called Chiesi USA
- 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici